FibroGen, Inc., is a biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of fibrosis, anaemia, cancer, and other serious unmet medical needs. FibroGens FG-3019 monoclonal antibody is in clinical development for treatment of idiopathic pulmonary fibrosis and other proliferative diseases, including pancreatic cancer and liver fibrosis. Another of FibroGen's candidates, FG-4592, is a small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase currently in late-stage clinical development for the treatment of anaemia. FibroGen is also developing FD-5200, a recombinant human type III collagens in synthetic corneas which is in late-stage clinical trials for the treatment of corneal blindness. FibroGen has a number of collaborations with pharmaceutical companies worldwide, including AstraZeneca, Aventis Pasteur, a unit of Aventis SA, and Taisho Pharmaceutical as well as Feasibility Agreements with more than thirty companies evaluating its novel biomaterials.
